Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action

TY - JOUR

T1 - Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action

AU - Andreasen, Jesper T

AU - Fitzpatrick, Ciaran M

AU - Larsen, Maria

AU - Skovgaard, Lars

AU - Nielsen, Simon D

AU - Clausen, Rasmus P

AU - Troelsen, Karin

AU - Pickering, Darryl S

N1 - Copyright © 2015 Elsevier B.V. All rights reserved.

PY - 2015/3/19

Y1 - 2015/3/19

N2 - Abstract Depression and anxiety often co-occur, and conventional monoamine-facilitating antidepressants show efficacy against symptoms in both disorders. Rodent studies indicate that antidepressant effects of monoamine-based antidepressants involve increased α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid glutamate receptor (AMPAR) neurotransmission, and positive allosteric modulators (PAMs) at AMPARs produced antidepressant-like effects in rodents. While this suggests that increased AMPAR-mediated neurotransmission is beneficial in depression management, preclinical studies addressing AMPARs in relation to anxiety have given ambiguous results with both anxiolytic-like and anxiogenic-like effects observed after AMPAR blockade. This study systematically compared the effects of the AMPAR potentiator LY451646 and the AMPAR antagonist GYKI-53655 on depression-related behaviour using the mouse forced swim (FST) and tail suspension tests (TST), and anxiety-related behaviour using the elevated zero maze (EZM), marble burying (MB) and novelty-induced hypophagia (NIH) tests. The serotonin-selective antidepressant citalopram was included for comparison. Due to the importance of AMPARs in learning and memory we also tested if GYKI-53655 disrupted performance in the V-maze test for attention-dependent behaviour, and the social transmission of food preference (STFP) test of long-term memory. LY451646 (3 mg/kg) showed an antidepressant-like profile in the FST and TST, and GYKI-53655 (≥5 mg/kg) had a depressogenic-like effect in the TST but no effect in the FST. Conversely, GYKI-53655 produced marked anxiolytic-like effects in the EZM (≥2.5 mg/kg), MBT (≥2.5 mg/kg), and NIH tests (≥5 mg/kg), while LY451646 (≥3 mg/kg) increased anxiety-like behaviour in the EZM. Citalopram showed an antidepressant-like effect in the FST (≥10 mg/kg), but not TST, an anxiolytic-like effect in the EZM (≥3 mg/kg) and MB test (≥2.5 mg/kg), and an anxiogenic-like effect in the NIH test (≥30 mg/kg). GYKI-53655 did not affect cognitive performance in the V-maze or STFP tests. Collectively, these findings suggest a differential role of AMPARs in depression and anxiety, with AMPAR activation promoting antidepressant responses and AMPAR inhibition promoting anxiolytic responses. The potential of AMPARs as a novel target in depression and anxiety pharmacotherapy is discussed.

AB - Abstract Depression and anxiety often co-occur, and conventional monoamine-facilitating antidepressants show efficacy against symptoms in both disorders. Rodent studies indicate that antidepressant effects of monoamine-based antidepressants involve increased α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid glutamate receptor (AMPAR) neurotransmission, and positive allosteric modulators (PAMs) at AMPARs produced antidepressant-like effects in rodents. While this suggests that increased AMPAR-mediated neurotransmission is beneficial in depression management, preclinical studies addressing AMPARs in relation to anxiety have given ambiguous results with both anxiolytic-like and anxiogenic-like effects observed after AMPAR blockade. This study systematically compared the effects of the AMPAR potentiator LY451646 and the AMPAR antagonist GYKI-53655 on depression-related behaviour using the mouse forced swim (FST) and tail suspension tests (TST), and anxiety-related behaviour using the elevated zero maze (EZM), marble burying (MB) and novelty-induced hypophagia (NIH) tests. The serotonin-selective antidepressant citalopram was included for comparison. Due to the importance of AMPARs in learning and memory we also tested if GYKI-53655 disrupted performance in the V-maze test for attention-dependent behaviour, and the social transmission of food preference (STFP) test of long-term memory. LY451646 (3 mg/kg) showed an antidepressant-like profile in the FST and TST, and GYKI-53655 (≥5 mg/kg) had a depressogenic-like effect in the TST but no effect in the FST. Conversely, GYKI-53655 produced marked anxiolytic-like effects in the EZM (≥2.5 mg/kg), MBT (≥2.5 mg/kg), and NIH tests (≥5 mg/kg), while LY451646 (≥3 mg/kg) increased anxiety-like behaviour in the EZM. Citalopram showed an antidepressant-like effect in the FST (≥10 mg/kg), but not TST, an anxiolytic-like effect in the EZM (≥3 mg/kg) and MB test (≥2.5 mg/kg), and an anxiogenic-like effect in the NIH test (≥30 mg/kg). GYKI-53655 did not affect cognitive performance in the V-maze or STFP tests. Collectively, these findings suggest a differential role of AMPARs in depression and anxiety, with AMPAR activation promoting antidepressant responses and AMPAR inhibition promoting anxiolytic responses. The potential of AMPARs as a novel target in depression and anxiety pharmacotherapy is discussed.

KW - Animals

KW - Anti-Anxiety Agents

KW - Antidepressive Agents

KW - Anxiety

KW - Behavior, Animal

KW - Benzodiazepines

KW - Depressive Disorder

KW - Female

KW - Maze Learning

KW - Mice

KW - Motor Activity

KW - Receptors, AMPA

KW - Sulfonamides

U2 - 10.1016/j.brainres.2015.01.001

DO - 10.1016/j.brainres.2015.01.001

M3 - Journal article

C2 - 25578259

SN - 0006-8993

VL - 1601

SP - 117

EP - 126

JO - Brain Research

JF - Brain Research

ER -